<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03879109</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2017/52</org_study_id>
    <nct_id>NCT03879109</nct_id>
  </id_info>
  <brief_title>Chemotherapy Followed by Pelvic Reirradiation Versus Chemotherapy Alone as Pre-operative Treatment for Locally Recurrent Rectal Cancer</brief_title>
  <acronym>GRECCAR15</acronym>
  <official_title>A Phase III Randomized Trial Evaluating Chemotherapy Followed by Pelvic Reirradiation Versus Chemotherapy Alone as Pre-operative Treatment for Locally Recurrent Rectal Cancer (GRECCAR - PRODIGE - FRENCH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      GRECCAR 15 is focused on Locally Recurrent Rectal Cancer (LRRC) for patients with previous
      pelvic radiotherapy for the primary rectal cancer. This situation leads to a 20% higher risk
      of non-curative resection for the LRRC management (R1 status) impacting significantly the
      overall survival. The widespread use of neoadjuvant radiotherapy for primary rectal cancer
      introduces this new problem: the treatment of LRRC in previously irradiated area.

      The objective of GRECCAR 15 is to assess the efficacy of neoadjuvant chemotherapy followed by
      pelvic reirradiation versus neoadjuvant chemotherapy alone on the rate of curative surgery
      (R0) in previously irradiated patients with LRRC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The incidence of rectal cancer in the European Union is 15-25/100 000 per year. There is a
      5-10% rate of locally recurrent rectal cancer (LRRC), with an overall survival rate of 40% at
      5 years after complete resection. Curative surgery of LRRC requires multi-visceral resections
      which are associated with significant post-operative morbidity of 60%. Despite the
      combination of a potential curability and the high post-operative morbidity, there are
      currently neither good data from prospective randomized studies regarding optimum
      preoperative treatments for LRRC nor is there data assessing the efﬁcacy of response to any
      such treatments. Moreover, the widespread use of neoadjuvant radiotherapy for primary cancer
      introduced a new problem: the treatment of LRRC in previously irradiated area. Some studies
      investigated various modalities of reirradiation and showed acceptable late toxicity and
      encouraging outcome. GRECCAR 15 would be the first prospective randomized trial so far to
      evaluate the interest of pelvic reirradiation for LRRC, in previously irradiated patients.

      The objective is to assess the efficacy of neoadjuvant chemotherapy followed by pelvic
      reirradiation versus neoadjuvant chemotherapy alone on the rate of curative surgery (R0) in
      previously irradiated patients with LRRC.

      Patients will be followed every 4 months during 2 years, and every 6 months the last year
      with chest, abdominal and pelvic scan and tumour markers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2019</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of curative surgery</measure>
    <time_frame>At surgery, expected average 6 to 8 weeks after neoadjuvant treatment</time_frame>
    <description>To determine the rate of R0 resection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>From surgery until 3 years of follow-up</time_frame>
    <description>Rate of disease-free survival at 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From surgery until 3 years of follow-up</time_frame>
    <description>Rate of overall survival at 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical morbidity</measure>
    <time_frame>From surgery until 30 days after surgery</time_frame>
    <description>To analyse surgical morbidity (Dindo classification) during first 30 days after the surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical mortality</measure>
    <time_frame>From surgery until 30 days after surgery</time_frame>
    <description>To analyse surgical mortality (Dindo classification) during first 30 days after the surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance to treatment</measure>
    <time_frame>From beginning of neoadjuvant treatment until surgery, expected average 20 weeks after neoadjuvant treatment</time_frame>
    <description>Proportion of patients receiving full allocated neoadjuvant treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of good tumor response</measure>
    <time_frame>At 6 weeks (Arm A) and 4 weeks (Arm B) after neoadjuvant treatment</time_frame>
    <description>Rate of tumor with a decreasing size of 50% at least after preoperative treatment at MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Before neoadjuvant treatment, before surgery, 4 months, one year and two years after surgery</time_frame>
    <description>To examine score of questionnaires QLQ CR-30, QLQ CR-29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance to treatment</measure>
    <time_frame>From beginning of neoadjuvant treatment until 1 year after surgery</time_frame>
    <description>Number of patients with adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Induction Chemotherapy followed by Pelvic reirradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Protocol of chemotherapy FOLFIRINOX*, 6 cycles :
oxaliplatin: 85 mg/m2
irinotecan: 180 mg/m²
folinic acid: 400 mg/m2
5FU : 400 mg/m2 (bolus)
5FU : 2400 mg/m2 (continuous infusion)
Protocol of reirradiation consists in conformational intensity modulated external irradiation, delivering a 30.6 Gy dose (1.8 Gy/day), with concomitant chemotherapy including Capecitabine 1600 mg/m²/day, five days a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Chemotherapy alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Protocol of chemotherapy FOLFIRINOX*, 6 cycles :
oxaliplatin: 85 mg/m2
irinotecan: 180 mg/m²
folinic acid: 400 mg/m2
5FU : 400 mg/m2 (bolus)
5FU : 2400 mg/m2 (continuous infusion)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy FOLFIRINOX, 6 cycles</intervention_name>
    <description>oxaliplatin: 85 mg/m2
irinotecan: 180 mg/m²
folinic acid: 400 mg/m2
5FU : 400 mg/m2 (bolus)
5FU : 2400 mg/m2 (continuous infusion)</description>
    <arm_group_label>Arm A: Induction Chemotherapy followed by Pelvic reirradiation</arm_group_label>
    <arm_group_label>Arm B: Chemotherapy alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiochemotherapy</intervention_name>
    <description>Reirradiation consists in conformational intensity modulated external irradiation (Intensity-modulated radiotherapy Volumetric Modulated Arc Therapy or tomotherapy) delivering a 30.6 Gy dose with high-energy photons in fractions of 1.8 Gy per day (17 fractions) 5 days a week With Concomitant chemotherapy including Capecitabine 1600 mg/m²/day, five days a week.</description>
    <arm_group_label>Arm A: Induction Chemotherapy followed by Pelvic reirradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Surgery will be performed at:
Arm A: 8 weeks (±1) after the end of treatment
Arm B: 6 weeks (±1) after the end of treatment
Surgical procedures are defined into three categories:
Total mesorectal excision (TME)
Extended-TEM (e-TME)
Pelvic exenteration (PE)</description>
    <arm_group_label>Arm A: Induction Chemotherapy followed by Pelvic reirradiation</arm_group_label>
    <arm_group_label>Arm B: Chemotherapy alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated informed consent

          -  Age ≥18 years

          -  LRRC (histologically proven) ≤ 15 cm from the anal verge

          -  First or second LRRC (histologically proven) ≤ 15 cm from the anal verge

          -  Previous pelvic irradiation for the primary rectal cancer or primary recurrence
             (25-50.4Gy)

          -  No distant metastasis

          -  Resectable locally recurrent rectal cancer (according to the International consensus,
             absolute contraindications for resectabililty are bilateral sciatic nerve involvement,
             circumferential bone involvement, high sacral involvement requiring total sacrectomy;
             relative contraindications for resectabilty are sciatic notch involvement and
             encasement external iliac vessels)

          -  Adequate hematologic function : Hemoglobin ≥ 9 g/dL, leukocytes ≥ 4000/mm3, neutrophil
             count ≥ 2000/mm3, blood platelets ≥ 100 000/mm3

          -  Adequate hepatic function : total bilirubin ≤ 1,5 x ULN, ASAT et ALAT ≤ 3 x ULN,
             alkalin phosphatases ≤ 3 x ULN

          -  Adequate renal function : creatinine clearance ≥ 50 ml/min

          -  ECOG performance status &lt; 2

          -  Women not sterilized by the first treatment (ovarian transposition) and males (and
             their female partners) patients agree to use two methods of effective contraception
             (one of them being a barrier method) during the study, for at least 6 months for men
             and 4 months for women after the last administration of study treatment

          -  Patient affiliated to a social security system or beneficiary of the same

          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory
             tests, and other study procedures

        Exclusion Criteria:

          -  Recurrent rectal cancer after local excision

          -  Concomitant cancer or medical history of cancer within 5 years other than cancers
             treated in situ (cervical carcinoma or basocellular carcinoma or spinocellular
             carcinoma)

          -  Contraindication for chemotherapy Contraindication for chemotherapy (refer to Summary
             of characteristics of the products of the study drugs available at
             http://base-donnees-publique.medicaments.gouv.fr) or radiotherapy or surgery

          -  Symptomatic cardiac or coronary insufficiency

          -  Personal or family history of long QT syndrome congenital

          -  ECG at screening or baseline (predose) with QT/QTc &gt; 450 msec (male) or QT/QTc &gt; 470
             msec (female)

          -  Chronic inflammatory bowel disease and/or bowel obstruction

          -  Patients with hypocalcemia, hypokalemia, hypomagnesemia.

          -  Progressive active infection (HIV or chronic hepatitis B or C) or any other severe
             medical condition that may preclude the delivery of treatment

          -  Complete or partial Dihydropyrimidine deshydrogenase (DPD) deficiency (uracilemia ≥ 16
             ng/mL)

          -  Peripheral neuropathy &gt; grade 1 (CTCAE grading system v5.0)

          -  Concomitant treatment with millepertuis, yellow fever vaccine, live attenuated
             vaccine, phenytoin, warfarin or sorivudine (or chemically equivalent)

          -  Pregnant or breast-feeding woman

          -  Persons deprived of liberty or under guardianship or incapable of giving consent

          -  Any psychological, familial, sociological or geographical condition potentially
             hampering compliance with the study protocol or follow-up schedule, as assessed by
             investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Quentin DENOST</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Quentin DENOST</last_name>
    <phone>(0)5 56 79 58 10</phone>
    <phone_ext>+33</phone_ext>
    <email>quentin.denost@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eric RULLIER</last_name>
    <email>eric.rullier@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent MINEUR</last_name>
      <email>l.mineur@isc84.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Besançon, Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zaher LAKKIS</last_name>
      <email>zaher.lakkis@free.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quentin DENOST</last_name>
      <email>quentin.denost@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David ORRY</last_name>
      <email>dorry@cgfl.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Luc FAUCHERON</last_name>
      <email>JLFaucheron@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehrad JAFARI</last_name>
      <email>m-jafari@o-lambret.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michel RIVOIRE</last_name>
      <email>rivoire@lyon.fnclcc.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon, HCL</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eddy COTTE</last_name>
      <email>eddy.cotte@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cécile DE CHAISEMARTIN</last_name>
      <email>dechaisemartinc@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe ROUANET</last_name>
      <email>phillipe.rouanet@montpellier.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adeline GERMAIN</last_name>
      <email>a.germain@chru-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Paris Saint-Joseph</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme LORIAU</last_name>
      <email>jloriau@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon - APHP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves PANIS</last_name>
      <email>yves.panis@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre - AP-HP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine BROUQUET</last_name>
      <email>antoine.brouquet@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou - APHP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard DOUARD</last_name>
      <email>richard.douard@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine - APHP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérémie LEFEVRE</last_name>
      <email>jeremie.lefevre@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis - APHP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent QUERO</last_name>
      <email>laurent.quero@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard MEUNIER</last_name>
      <email>bernard.meunier@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Jacques TUECH</last_name>
      <email>jean-jacques.tuech@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Saint-Herblain</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel RIO</last_name>
      <email>emmanuel.rio@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent GHOUTI</last_name>
      <email>ghouti.l@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 13, 2019</study_first_submitted>
  <study_first_submitted_qc>March 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Locally recurrent rectal cancer</keyword>
  <keyword>Pelvic reirradiation</keyword>
  <keyword>Oncological surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folfirinox</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

